March 27, 2008 — NewYork-Presbyterian Hospital/Weill Cornell Medical Center is recruiting patients for a national clinical research study of an investigational implantable device designed to help those with type-2 diabetes who are overweight and do not respond to current oral anti-diabetic treatments.The Tantalus® System is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation when a person eats. The device is implanted though a minimally invasive laparoscopic procedure that can be performed in an outpatient setting...
...NewYork-Presbyterian/Weill Cornell is one of thirty sites in the U.S. participating in the study, which is funded by MetaCure, the manufacturer of Tantalus. The device is currently CE-marked in Europe.... Weill Cornell Medical Center's Press Release -
